** Sun Pharmaceutical SUN.NS gains 4.4% in holiday-curtailed week; set for best weekly performance since late September 2024
** Drugmaker top weekly gainer on Nifty 50 .NSEI and pharma .NIPHARM indexes
** SUN gained in all sessions this week after $355 million deal for Checkpoint Therapeutics CKPT.O
** Analysts backed the deal, saying it would complement SUN's specialty portfolio
** Stock rated "buy" on avg, per data compiled by LSEG
** YTD, SUN down 11% vs NSEI's 4.7% drop
(Reporting by Nandan Mandayam in Bengaluru)
((Nandan.Mandayam@thomsonreuters.com; Mobile: +91 9591011727;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。